![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: FLOT2 |
Gene summary for FLOT2 |
![]() |
Gene information | Species | Human | Gene symbol | FLOT2 | Gene ID | 2319 |
Gene name | flotillin 2 | |
Gene Alias | ECS-1 | |
Cytomap | 17q11.2 | |
Gene Type | protein-coding | GO ID | GO:0001765 | UniProtAcc | J3QLD9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2319 | FLOT2 | P48T-E | Human | Esophagus | ESCC | 3.67e-40 | 6.53e-01 | 0.0959 |
2319 | FLOT2 | P49T-E | Human | Esophagus | ESCC | 1.80e-07 | 1.08e+00 | 0.1768 |
2319 | FLOT2 | P52T-E | Human | Esophagus | ESCC | 3.35e-39 | 7.73e-01 | 0.1555 |
2319 | FLOT2 | P54T-E | Human | Esophagus | ESCC | 2.78e-73 | 2.21e+00 | 0.0975 |
2319 | FLOT2 | P56T-E | Human | Esophagus | ESCC | 6.89e-11 | 1.02e+00 | 0.1613 |
2319 | FLOT2 | P57T-E | Human | Esophagus | ESCC | 3.10e-28 | 5.68e-01 | 0.0926 |
2319 | FLOT2 | P61T-E | Human | Esophagus | ESCC | 1.11e-24 | 8.50e-01 | 0.099 |
2319 | FLOT2 | P62T-E | Human | Esophagus | ESCC | 8.67e-63 | 1.13e+00 | 0.1302 |
2319 | FLOT2 | P65T-E | Human | Esophagus | ESCC | 1.01e-27 | 6.86e-01 | 0.0978 |
2319 | FLOT2 | P74T-E | Human | Esophagus | ESCC | 1.39e-36 | 9.97e-01 | 0.1479 |
2319 | FLOT2 | P75T-E | Human | Esophagus | ESCC | 1.19e-17 | 3.62e-01 | 0.1125 |
2319 | FLOT2 | P76T-E | Human | Esophagus | ESCC | 9.91e-53 | 9.34e-01 | 0.1207 |
2319 | FLOT2 | P79T-E | Human | Esophagus | ESCC | 3.49e-21 | 4.57e-01 | 0.1154 |
2319 | FLOT2 | P80T-E | Human | Esophagus | ESCC | 7.78e-39 | 1.35e+00 | 0.155 |
2319 | FLOT2 | P82T-E | Human | Esophagus | ESCC | 5.00e-15 | 1.01e+00 | 0.1072 |
2319 | FLOT2 | P83T-E | Human | Esophagus | ESCC | 7.98e-57 | 1.58e+00 | 0.1738 |
2319 | FLOT2 | P84T-E | Human | Esophagus | ESCC | 9.54e-11 | 8.63e-01 | 0.0933 |
2319 | FLOT2 | P89T-E | Human | Esophagus | ESCC | 1.19e-27 | 1.66e+00 | 0.1752 |
2319 | FLOT2 | P91T-E | Human | Esophagus | ESCC | 2.94e-14 | 1.47e+00 | 0.1828 |
2319 | FLOT2 | P107T-E | Human | Esophagus | ESCC | 3.35e-52 | 1.31e+00 | 0.171 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0031647111 | Esophagus | ESCC | regulation of protein stability | 223/8552 | 298/18723 | 5.76e-25 | 1.52e-22 | 223 |
GO:0050821111 | Esophagus | ESCC | protein stabilization | 140/8552 | 191/18723 | 6.50e-15 | 3.61e-13 | 140 |
GO:0072659110 | Esophagus | ESCC | protein localization to plasma membrane | 193/8552 | 284/18723 | 1.95e-14 | 1.03e-12 | 193 |
GO:199077819 | Esophagus | ESCC | protein localization to cell periphery | 217/8552 | 333/18723 | 4.08e-13 | 1.88e-11 | 217 |
GO:003070518 | Esophagus | ESCC | cytoskeleton-dependent intracellular transport | 133/8552 | 195/18723 | 1.48e-10 | 4.27e-09 | 133 |
GO:000716320 | Esophagus | ESCC | establishment or maintenance of cell polarity | 143/8552 | 218/18723 | 2.05e-09 | 4.65e-08 | 143 |
GO:001097013 | Esophagus | ESCC | transport along microtubule | 107/8552 | 155/18723 | 3.17e-09 | 6.80e-08 | 107 |
GO:000808810 | Esophagus | ESCC | axo-dendritic transport | 58/8552 | 75/18723 | 2.09e-08 | 4.02e-07 | 58 |
GO:004578527 | Esophagus | ESCC | positive regulation of cell adhesion | 255/8552 | 437/18723 | 5.07e-08 | 9.11e-07 | 255 |
GO:003001018 | Esophagus | ESCC | establishment of cell polarity | 96/8552 | 143/18723 | 1.69e-07 | 2.67e-06 | 96 |
GO:000854410 | Esophagus | ESCC | epidermis development | 193/8552 | 324/18723 | 2.87e-07 | 4.19e-06 | 193 |
GO:00510908 | Esophagus | ESCC | regulation of DNA-binding transcription factor activity | 252/8552 | 440/18723 | 5.22e-07 | 6.97e-06 | 252 |
GO:00510918 | Esophagus | ESCC | positive regulation of DNA-binding transcription factor activity | 155/8552 | 260/18723 | 3.83e-06 | 4.14e-05 | 155 |
GO:00991114 | Esophagus | ESCC | microtubule-based transport | 115/8552 | 190/18723 | 2.54e-05 | 2.15e-04 | 115 |
GO:00510926 | Esophagus | ESCC | positive regulation of NF-kappaB transcription factor activity | 91/8552 | 152/18723 | 2.91e-04 | 1.75e-03 | 91 |
GO:00440918 | Esophagus | ESCC | membrane biogenesis | 38/8552 | 55/18723 | 3.78e-04 | 2.19e-03 | 38 |
GO:00717099 | Esophagus | ESCC | membrane assembly | 35/8552 | 50/18723 | 4.33e-04 | 2.44e-03 | 35 |
GO:002240720 | Esophagus | ESCC | regulation of cell-cell adhesion | 239/8552 | 448/18723 | 5.88e-04 | 3.19e-03 | 239 |
GO:004211018 | Esophagus | ESCC | T cell activation | 256/8552 | 487/18723 | 1.18e-03 | 5.87e-03 | 256 |
GO:002240919 | Esophagus | ESCC | positive regulation of cell-cell adhesion | 155/8552 | 284/18723 | 1.50e-03 | 7.06e-03 | 155 |
Page: 1 2 3 4 5 6 7 8 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa049109 | Esophagus | ESCC | Insulin signaling pathway | 89/4205 | 137/8465 | 1.97e-04 | 7.32e-04 | 3.75e-04 | 89 |
hsa0491014 | Esophagus | ESCC | Insulin signaling pathway | 89/4205 | 137/8465 | 1.97e-04 | 7.32e-04 | 3.75e-04 | 89 |
hsa0491021 | Liver | Cirrhotic | Insulin signaling pathway | 56/2530 | 137/8465 | 3.74e-03 | 1.50e-02 | 9.26e-03 | 56 |
hsa0491031 | Liver | Cirrhotic | Insulin signaling pathway | 56/2530 | 137/8465 | 3.74e-03 | 1.50e-02 | 9.26e-03 | 56 |
hsa0491041 | Liver | HCC | Insulin signaling pathway | 95/4020 | 137/8465 | 1.53e-07 | 1.97e-06 | 1.10e-06 | 95 |
hsa0491051 | Liver | HCC | Insulin signaling pathway | 95/4020 | 137/8465 | 1.53e-07 | 1.97e-06 | 1.10e-06 | 95 |
hsa049108 | Oral cavity | OSCC | Insulin signaling pathway | 83/3704 | 137/8465 | 4.83e-05 | 2.00e-04 | 1.02e-04 | 83 |
hsa0491013 | Oral cavity | OSCC | Insulin signaling pathway | 83/3704 | 137/8465 | 4.83e-05 | 2.00e-04 | 1.02e-04 | 83 |
hsa0491022 | Prostate | Tumor | Insulin signaling pathway | 44/1791 | 137/8465 | 1.69e-03 | 7.10e-03 | 4.40e-03 | 44 |
hsa0491032 | Prostate | Tumor | Insulin signaling pathway | 44/1791 | 137/8465 | 1.69e-03 | 7.10e-03 | 4.40e-03 | 44 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FLOT2 | SNV | Missense_Mutation | rs751666905 | c.1009N>A | p.Glu337Lys | p.E337K | Q14254 | protein_coding | deleterious(0) | possibly_damaging(0.87) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
FLOT2 | SNV | Missense_Mutation | c.151N>G | p.Thr51Ala | p.T51A | Q14254 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
FLOT2 | SNV | Missense_Mutation | rs376080270 | c.82N>A | p.Val28Met | p.V28M | Q14254 | protein_coding | deleterious(0.02) | benign(0.378) | TCGA-D8-A1Y1-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | PD |
FLOT2 | SNV | Missense_Mutation | rs374807903 | c.163N>T | p.Arg55Cys | p.R55C | Q14254 | protein_coding | deleterious(0.02) | possibly_damaging(0.835) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
FLOT2 | SNV | Missense_Mutation | c.706N>A | p.Glu236Lys | p.E236K | Q14254 | protein_coding | deleterious(0.05) | possibly_damaging(0.627) | TCGA-EK-A2RN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
FLOT2 | SNV | Missense_Mutation | c.142G>C | p.Glu48Gln | p.E48Q | Q14254 | protein_coding | deleterious(0.02) | probably_damaging(0.91) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
FLOT2 | SNV | Missense_Mutation | c.902N>T | p.Ala301Val | p.A301V | Q14254 | protein_coding | deleterious(0) | probably_damaging(0.96) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
FLOT2 | SNV | Missense_Mutation | rs376080270 | c.82N>A | p.Val28Met | p.V28M | Q14254 | protein_coding | deleterious(0.02) | benign(0.378) | TCGA-AZ-4615-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | xeloda | PD |
FLOT2 | SNV | Missense_Mutation | c.945G>T | p.Glu315Asp | p.E315D | Q14254 | protein_coding | tolerated(0.11) | benign(0.011) | TCGA-D5-6930-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
FLOT2 | SNV | Missense_Mutation | c.1251N>G | p.Ile417Met | p.I417M | Q14254 | protein_coding | tolerated(0.06) | benign(0.005) | TCGA-G4-6586-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |